These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33765428)

  • 21. Biomarker clusters are differentially associated with longitudinal cognitive decline in late midlife.
    Racine AM; Koscik RL; Berman SE; Nicholas CR; Clark LR; Okonkwo OC; Rowley HA; Asthana S; Bendlin BB; Blennow K; Zetterberg H; Gleason CE; Carlsson CM; Johnson SC
    Brain; 2016 Aug; 139(Pt 8):2261-74. PubMed ID: 27324877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.
    Gleason CE; Norton D; Anderson ED; Wahoske M; Washington DT; Umucu E; Koscik RL; Dowling NM; Johnson SC; Carlsson CM; Asthana S;
    J Alzheimers Dis; 2018; 61(1):79-89. PubMed ID: 29125485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples.
    Wolfsgruber S; Molinuevo JL; Wagner M; Teunissen CE; Rami L; Coll-Padrós N; Bouwman FH; Slot RER; Wesselman LMP; Peters O; Luther K; Buerger K; Priller J; Laske C; Teipel S; Spottke A; Heneka MT; Düzel E; Drzezga A; Wiltfang J; Sikkes SAM; van der Flier WM; Jessen F;
    Alzheimers Res Ther; 2019 Jan; 11(1):8. PubMed ID: 30654834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of CSF Biomarkers With Hippocampal-Dependent Memory in Preclinical Alzheimer Disease.
    Trelle AN; Carr VA; Wilson EN; Swarovski MS; Hunt MP; Toueg TN; Tran TT; Channappa D; Corso NK; Thieu MK; Jayakumar M; Nadiadwala A; Guo W; Tanner NJ; Bernstein JD; Litovsky CP; Guerin SA; Khazenzon AM; Harrison MB; Rutt BK; Deutsch GK; Chin FT; Davidzon GA; Hall JN; Sha SJ; Fredericks CA; Andreasson KI; Kerchner GA; Wagner AD; Mormino EC
    Neurology; 2021 Mar; 96(10):e1470-e1481. PubMed ID: 33408146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data.
    Guhra M; Thomas C; Boedeker S; Kreisel S; Driessen M; Beblo T; Ohrmann P; Toepper M
    Exp Gerontol; 2016 Jan; 73():107-13. PubMed ID: 26585048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition.
    Reijs BLR; Ramakers IHGB; Elias-Sonnenschein L; Teunissen CE; Koel-Simmelink M; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Johannsen P; Vanderstichele H; Verhey F; Devanand DP; Visser PJ
    J Alzheimers Dis; 2017; 60(3):1025-1034. PubMed ID: 28984603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly.
    Svenningsson AL; Stomrud E; Insel PS; Mattsson N; Palmqvist S; Hansson O
    Sci Rep; 2019 Aug; 9(1):11180. PubMed ID: 31371787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The recency ratio is related to CSF amyloid beta 1-42 levels in MCI-AD.
    Bruno D; Gleason CE; Koscik RL; Pomara N; Zetterberg H; Blennow K; Johnson SC
    Int J Geriatr Psychiatry; 2019 Mar; 34(3):415-419. PubMed ID: 30430632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.
    Yau WW; Tudorascu DL; McDade EM; Ikonomovic S; James JA; Minhas D; Mowrey W; Sheu LK; Snitz BE; Weissfeld L; Gianaros PJ; Aizenstein HJ; Price JC; Mathis CA; Lopez OL; Klunk WE
    Lancet Neurol; 2015 Aug; 14(8):804-813. PubMed ID: 26139022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer's Disease.
    Hey JA; Abushakra S; Blennow K; Reiman EM; Hort J; Prins ND; Sheardova K; Kesslak P; Shen L; Zhu X; Albayrak A; Paul J; Schaefer JF; Power A; Tolar M
    Drugs; 2024 Jul; 84(7):811-823. PubMed ID: 38902571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Choroid plexus volume as a novel candidate neuroimaging marker of the Alzheimer's continuum.
    Jiang J; Zhuo Z; Wang A; Li W; Jiang S; Duan Y; Ren Q; Zhao M; Wang L; Yang S; Awan MUN; Liu Y; Xu J
    Alzheimers Res Ther; 2024 Jul; 16(1):149. PubMed ID: 38961406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Better verbal memory in women than men in MCI despite similar levels of hippocampal atrophy.
    Sundermann EE; Biegon A; Rubin LH; Lipton RB; Mowrey W; Landau S; Maki PM;
    Neurology; 2016 Apr; 86(15):1368-1376. PubMed ID: 26984945
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Memory performance mediates subjective sleep quality associations with cerebrospinal fluid Alzheimer's disease biomarker levels and hippocampal volume among individuals with mild cognitive symptoms.
    Stankeviciute L; Blackman J; Tort-Colet N; Fernández-Arcos A; Sánchez-Benavides G; Suárez-Calvet M; Iranzo Á; Molinuevo JL; Gispert JD; Coulthard E; Grau-Rivera O
    J Sleep Res; 2024 Aug; 33(4):e14108. PubMed ID: 38035770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuropsychiatric Symptoms and Alzheimer's Disease Biomarkers Predict Driving Decline: Brief Report.
    Babulal GM; Stout SH; Head D; Holtzman DM; Fagan AM; Morris JC; Roe CM
    J Alzheimers Dis; 2017; 58(3):675-680. PubMed ID: 28453487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin-like growth factor binding protein-2 interactions with Alzheimer's disease biomarkers.
    Lane EM; Hohman TJ; Jefferson AL;
    Brain Imaging Behav; 2017 Dec; 11(6):1779-1786. PubMed ID: 27817134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers.
    Casaletto KB; Elahi FM; Bettcher BM; Neuhaus J; Bendlin BB; Asthana S; Johnson SC; Yaffe K; Carlsson C; Blennow K; Zetterberg H; Kramer JH
    Neurology; 2017 Oct; 89(17):1782-1788. PubMed ID: 28939668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.